Abstract
HMGA proteins are thought to be causally involved in the progression of different diseases, including benign and malignant tumors, obesity, arteriosclerosis, and restenosis. As HMGA proteins are architectural transcription factors, their binding to DNA leads to changes in DNA-conformation modulating the environment for the assembly and function of transcriptional complexes, thus influencing the expression of a huge variety of genes. Despite the emerging role of HMGA proteins for important diseases, only limited information is available about mechanisms regulating the expression of the HMGA2 gene. In this report, 2240 bp of the 5′ flanking region of the HMGA2 gene were functionally analyzed by luciferase assay experiments. Besides the identification of novel positive and negative regulatory elements, it was shown that transcription is initiated from two independent promoter regions within cell lines HeLa, MCF7, and L14TSV 40. Furthermore, a functional polymorphic dinucleotide repeat (TCTCT(TC)n) 500 bp upstream of the ATG translational start codon was found to regulate strongly the human HMGA2 promoter with an activation pattern that correlates to its TC-repeat length.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anand A and Chada K . (2000). Nat. Genet., 24, 377–380.
Ashar HR, Cherath L, Przybysz KM and Chada K . (1996). Genomics, 31, 207–214.
Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC and Chada K . (1995). Cell, 82, 57–65.
Ayoubi TA, Jansen E, Meulemans SM and Van de Ven WJ (1999). Oncogene, 18, 5076–5087.
Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM and Fusco A . (1999). Cancer Res., 59, 4793–4797.
Borrmann L, Wilkening S and Bullerdiek J . (2001). Oncogene, 20, 4537–4541.
Bustin M and Reeves R . (1996). Prog. Nucleic Acid Res. Mol. Biol., 54, 35–100.
Chau KY, Arlotta P, Patel UA, Crane-Robinson C, Manfioletti G and Ono SJ . (1999). FEBS Lett., 457, 429–436.
Chau KY, Patel UA, Lee KL, Lam HY and Crane-Robinson C . (1995). Nucleic Acids Res., 23, 4262–4266.
Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A and Fusco A . (1996). Oncogene, 13, 2439–2446.
Chin MT, Pellacani A, Hsieh CM, Lin SS, Jain MK, Patel A and Huggins GS . (1999). J. Mol. Cell Cardiol., 31, 2199–2205.
Espinas ML, Jimenez-Garcia E, Martinez-Balbas A and Azorin F . (1996). J. Biol. Chem., 271, 31807–31812.
Firulli AB, Maibenco DC and Kinniburgh AJ . (1994). Arch. Biochem. Biophys., 310, 236–242.
Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J and Hameister H . (1998). Genes Chromosomes Cancer, 23, 350–357.
Htun H and Dahlberg JE . (1988). Science, 241, 1791–1796.
Htun H and Dahlberg JE . (1989). Science, 243, 1571–1576.
Ishwad CS, Shriver MD, Lassige DM and Ferrell RE . (1997). Hum. Genet., 99, 103–105.
Kazmierczak B, Rosigkeit J, Wanschura S, Meyer-Bolte K, Van de Ven WJ, Kayser K, Krieghoff B, Kastendiek H, Bartnitzke S and Bullerdiek J . (1996). Oncogene, 12, 515–521.
Kim HG, Reddoch JF, Mayfield C, Ebbinghaus S, Vigneswaran N, Thomas S, Jones Jr DE and Miller DM . (1998). Biochemistry, 37, 2299–2304.
Lu Q, Wallrath LL, Granok H and Elgin SC . (1993). Mol. Cell. Biol., 13, 2802–2814.
Meilahn EN, Matthews KA, Egeland G, and Kelsey SF . (1989). Maturitas, 11, 319–329
Michel D, Chatelain G, Herault Y and Brun G . (1992). Nucleic Acids Res., 20, 439–443.
Patel UA, Bandiera A, Manfioletti G, Giancotti V, Chau KY and Crane-Robinson C . (1994). Biochem. Biophys. Res. Commun., 201, 63–70.
Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U and Bullerdiek J . (1996). Am. J. Pathol., 149, 775–779.
Rustighi A, Mantovani F, Fusco A, Giancotti V and Manfioletti G . (1999). Biochem. Biophys. Res. Commun., 265, 439–447.
Rustighi A, Tessari MA, Vascotto F, Sgarra R, Giancotti V and Manfioletti G . (2002). Biochemistry, 41, 1229–1240.
Scala S, Portella G, Fedele M, Chiappetta G and Fusco A . (2000). Proc. Natl. Acad. Sci. USA, 97, 4256–4261.
Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H and Van de Ven WJ . (1995). Nat. Genet., 10, 436–444.
Solomon MJ, Strauss F and Varshavsky A . (1986). Proc. Natl. Acad. Sci. USA, 83, 1276–1280.
Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM and Schalken JA . (1996). Br. J. Cancer, 74, 573–578.
Zhou X, Benson KF, Ashar HR and Chada K . (1995). Nature, 376, 771–774.
Acknowledgements
This work was supported by a grant from the Deutsche Forschungsgemeinschaft (Bu 592/4-3).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borrmann, L., Seebeck, B., Rogalla, P. et al. Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat. Oncogene 22, 756–760 (2003). https://doi.org/10.1038/sj.onc.1206073
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206073
Keywords
This article is cited by
-
Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele
Human Genetics (2009)
-
Nucleotide sequence analyses of the MRP 1 gene in four populations suggest negative selection on its coding region
BMC Genomics (2006)
-
Dinucleotide repeats negatively modulate the promoter activity of Cyr61 and is unstable in hepatocellular carcinoma patients
Oncogene (2005)